Highlights
- Oakridge returned to full-year profit in FY2026 and reported positive Operating Cash Flow alongside higher Revenue and other income.
- Oakridge develops nurse call hardware and software through its NuCaMS and NuCaMS Enterprise platforms for care providers.
- Oakridge supplies Assistive Technology to hospitals, aged care facilities, disability care providers and supported independent living operators.
- A substantial holder notice showed Montague’s interest rising to about 52.81%, giving it a majority stake in Oakridge.
Oakridge International Limited (ASX:OAK) is one of the smallest companies on the ASX by market value, yet its latest audited accounts show something many micro-caps cannot claim: a full-year profit and positive operating cash flow. The Adelaide-based company designs and sells nurse call and assistive technology for hospitals, aged care, disability care and supported independent living, and its FY2026 results point to a small but trading Business rather than a pre-revenue concept.
What Oakridge does
Oakridge develops and distributes its own nurse call hardware and software, centred on its NuCaMS and NuCaMS Enterprise platforms. Products include wireless nurse call systems, resident pendants, call points and real-time location system (RTLS) implementations, sold directly and through regional partners.
According to the FY2026 annual financial report dated 24 August 2026, development work during the year included a first stage of enterprise reporting, completion of RTLS call point and resident pendant projects, and validation of cloud integration with Microsoft Azure. The company says its roadmap is aligned with the AS8311:2024 nurse call standard.
FY2026 results
Of that, sales revenue from contracts with customers was about AUD 3.09 million, with a Research and Development tax concession of about AUD 350,000 making up most of the balance.
Oakridge recorded a profit after tax of about AUD 109,000, compared with a loss of about AUD 129,000 a year earlier. Operating cash flow was an inflow of about AUD 127,000, and cash at 30 June 2026 was about AUD 638,000, up from about AUD 469,000. Net Assets were about AUD 1.36 million, although accumulated losses stood at about AUD 28.4 million, a legacy of the company's earlier history.
Funding and ownership
During FY2026 the company issued about 5 million shares for roughly AUD 350,000 to Montague Capital, an entity associated with chairman Con Unerkov, on the exercise of options. A substantial holder notice shows Montague's interest rising to about 52.81%, giving one Shareholder majority control.
The board says it is consulting legal advisers on the Teko matter.
Share Trading on 16 November
That implies a Market Capitalisation of about AUD 1.95 million. The company did lodge notices on 15 November 2026 regarding the expiry of unlisted options.
Risks and what to watch
Oakridge operates in a specialised segment where larger nurse call suppliers compete for hospital and aged care contracts, and project timing can make revenue lumpy. Its cash buffer is modest, the profit Margin is thin and partly supported by the R&D tax concession, and the concentrated shareholding and thin trading limit liquidity. The Teko matter remains unresolved.
Management guidance in the Annual Report is that channel activity and project conversions should support revenue into FY2027, and the company is evaluating adjacent opportunities, including possible AI applications, which it describes as early stage. Near-term items include its annual general meeting, for which a notice was lodged on 25 October 2026, and the next quarterly cash flow report due in late January 2027.
_11_16_2026_07_52_44_870464.jpg)




_11_16_2026_07_55_02_604226.jpg)
Please wait processing your request...